Abstract:Since injection administration for diabetes is invasive, it is important to develop an effective transdermal method for insulin. However, transdermal delivery remains challenging owing to the strong barrier function of the stratum corneum (SC) of the skin. Here, we developed ionic liquid (IL)-in-oil microemulsion formulations (MEFs) for transdermal insulin delivery using choline-fatty acids ([Chl][FAs])-comprising three different FAs (C18:0, C18:1, and C18:2)-as biocompatible surface-active ILs (SAILs). The MEFs were successfully developed using [Chl][FAs] as surfactants, sorbitan monolaurate (Span-20) as a cosurfactant, choline propionate IL as an internal polar phase, and isopropyl myristate as a continuous oil phase. Ternary phase behavior, dynamic light scattering, and transmission electron microscopy studies revealed that MEFs were thermodynamically stable with nanoparticle size. The MEFs significantly enhanced the transdermal permeation of insulin via the intercellular route by compromising the tight lamellar structure of SC lipids through a fluidity-enhancing mechanism. In vivo transdermal administration of low insulin doses (50 IU/kg) to diabetic mice showed that MEFs reduced blood glucose levels (BGLs) significantly compared with a commercial surfactant-based formulation by increasing the bioavailability of insulin in the systemic circulation and sustained the insulin level for a much longer period (half-life > 24 h) than subcutaneous injection (half-life 1.32 h). When [Chl][C18:2] SAIL-based MEF was transdermally administered, it reduced the BGL by 56% of its initial value. The MEFs were biocompatible and nontoxic (cell viability > 90%). They remained stable at room temperature for 3 months and their biological activity was retained for 4 months at 4 °C. We believe SAIL-based MEFs will alter current approaches to insulin therapy and may be a potential transdermal nanocarrier for protein and peptide delivery.

Enhancing the Solubility and Transdermal Delivery of Drugs Using Ionic Liquid‐In‐Oil Microemulsions

Enhanced Transdermal Delivery of Insulin by Choline-Based Ionic Liquids

Improving Dermal Delivery of Hydrophilic Macromolecules by Biocompatible Ionic Liquid Based on Choline and Malic Acid.

Insulin Transdermal Delivery System for Diabetes Treatment Using a Biocompatible Ionic Liquid-Based Microemulsion.

Oral Ionic Liquid for Transdermal Delivery and Obesity Treatment

Ionic Liquids for Enhanced Drug Delivery: Recent Progress and Prevailing Challenges

Ionic liquid transdermal delivery system: Progress, prospects, and challenges

Ionic Liquids: Promising Approach for Oral Drug Delivery

Ionic liquids as the effective technology for enhancing transdermal drug delivery: Design principles, roles, mechanisms, and future challenges

Preparation of microcapsules containing ionic liquids with a new solvent extraction system

Ionic liquid-mediated ethosome for transdermal delivery of insulin

Liquid Formulations Based on Ionic Liquids in Biomedicine

Ionic Liquids-Based Drug Delivery: a Perspective

Effects of imidazolium ionic liquids on skin barrier lipids – Perspectives for drug delivery

Ionic Liquids: Green and Tailor-Made Solvents in Drug Delivery

The molecular assembly of the ionic liquid/aliphatic carboxylic acid/aliphatic amine as effective and safety transdermal permeation enhancers

Ionic Liquid-Based patch formulation for enhanced transdermal delivery of sparingly soluble drug

Design Principles and Applications of Ionic Liquids for Transdermal Drug Delivery

Biocompatible ionic liquid enhances transdermal antigen peptide delivery and preventive vaccination effect.

An insight into pharmaceutical challenges with ionic liquids: where do we stand in transdermal delivery?

The Development and Characterization of Novel Ionic Liquids Based on Mono- and Dicarboxylates with Meglumine for Drug Solubilizers and Skin Permeation Enhancers